Syros Pharmaceuticals Inc. (SYRS)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Nancy A. Simonian |
| Employees: | 120 |
| Web site: | syros.com |
|
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140
617-744-1340
| |
| Date | Ratio |
|---|---|
| 2022-09-19 | 1:10 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.
Please log in first to see chart